EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy

Hagar Elghazawy iD, Mahmoud Elghazawy iD, Hamdy A Azim, Mariam B Abouelkhair, Sara Hossam, Shazneil Briones, Paul A Townsend, Olivier N F Cexus, Laila M Farid

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Hagar Elghazawy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data exists about the associations between TROP2 protein, clinico-pathological characteristics, and outcomes in patients with an early HR+/HER2- breast cancer (BC). Patients and Methods TROP2 membranous expression was assessed on tumor biopsy by immunohistochemistry (IHC) in 70 consecutive patients with HR+/HER2− BC who are eligible for neoadjuvant chemotherapy (NAC). TROP2 expression was correlated to initial clinico-pathological parameters and pathological response post-NAC. Furthermore, Transcriptomics analysis of TACSTD2 using SCAN-B and GSE81538 datasets was performed and correlated with clinico-pathological parameters and survival.

Results

All patients showed TROP2 IHC expression, with intermediate and high expression in 68.57% and 31.43%, respectively. High TROP2 expression showed a significant correlation with high Ki-67 pre-NAC (P = .017), while no significant correlation with pCR or residual cancer burden. High TACSTD2 expression was associated with significantly lower histological grade (P < .0001), earlier tumor stage (P < .0001), smaller tumor size (< 20 mm, P < .0001), lower Ki-67 (P < .0001), and longer overall-survival (HR = 0.76; P = .0008), recurrence-free survival (RFS; HR = 0.64; P = .0001) and distant-RFS (HR = 0.64; P = .0011).

Conclusions

In this study, TROP2 expression by IHC was observed in all HR+/HER2− BC cases, and was not significantly correlated with pCR to NAC. In contrast, TACSTD2 expression, which was significantly positively correlated with survival in the same population, suggests a favorable prognostic value at the transcript level. This finding warrants further investigation in future studies, particularly focusing on TACSTD2 expression at the mRNA rather than the protein level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCell Adhesion MoleculesAntigens, NeoplasmErb-b2 Receptor Tyrosine KinasesHumansFemaleNeoadjuvant TherapyMiddle AgedAdultAgedBiomarkers, TumorPrognosisChemotherapy, Adjuvant

Stichwörter der Autor:innen

TACSTD2HER2TROP2biomarkerbreast cancerprognosis

Substanzen

Cell Adhesion MoleculesAntigens, NeoplasmErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorTACSTD2 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
  • Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Research and Innovation Section, University of Stirling, Stirling, UK.

ORCID-Profile: Hagar Elghazawy, Mahmoud Elghazawy

Zitieren

APA

Elghazawy, H., Elghazawy, M., Azim, H. A., Abouelkhair, M. B., Hossam, S., Briones, S., Townsend, P. A., Cexus, O. N. F., & Farid, L. M. (2025). Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyaf184

Vancouver

Elghazawy H, Elghazawy M, Azim HA, Abouelkhair MB, Hossam S, Briones S, et al. Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy. The Oncologist. 2025. doi:10.1093/oncolo/oyaf184

BibTeX
@article{Elghazawy2025,
  author = {Elghazawy, Hagar and Elghazawy, Mahmoud and Azim, Hamdy A and Abouelkhair, Mariam B and Hossam, Sara and Briones, Shazneil and Townsend, Paul A and Cexus, Olivier N F and Farid, Laila M},
  title = {Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf184}
}
Kostenlos starten →